SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. [electronic resource]
Producer: 20170814Description: 250-255 p. digitalISSN:- 1546-170X
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Animals
- Antimetabolites, Antineoplastic -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis -- drug effects
- Cell Line, Tumor
- Cytarabine -- administration & dosage
- Daunorubicin -- administration & dosage
- Disease Models, Animal
- Female
- Flow Cytometry
- Humans
- Immunoblotting
- Leukemia, Myeloid, Acute -- drug therapy
- Male
- Middle Aged
- Monomeric GTP-Binding Proteins -- metabolism
- Prognosis
- Retrospective Studies
- SAM Domain and HD Domain-Containing Protein 1
- Young Adult
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.